Session 3B: The role of Disrupters of BMP9 (DONs) in regulating bone tumor formation from mesenchymal stem cells
Session Number
Session 3B: 2nd Presentation
Advisor(s)
Dr. Tong-Chuan He, University of Chicago
Location
Lecture Hall
Start Date
26-4-2018 12:40 PM
End Date
26-4-2018 1:25 PM
Abstract
It has become increasingly well-known that osteosarcoma is not only a genetic disease, but also a differentiation one that results from an osteoblast differentiation and proliferation imbalance. This study investigated how certain 19-base short regulatory RNAs may disrupt BMP9-induced osteoblast differentiation in mesenchymal stem cells (MSCs). We are interested in determining these effects because they may further explain the development of osteosarcoma.
Dr. He introduced a completely randomized 19-base short RNA Library into MSCs and discovered several short RNA transcripts, which are named as Disruptors of BMP9 (DONs). These DONs were shown to produce osteogenic resistant MSCs. Our candidate DONs are now being tested for their ability to disrupt osteogenic differentiation in MSCs. Within the coming months, we hope to uncover effective DONs and sequence its RNA to determine any up or down regulation of mRNA or lncRNA involved in the pathogenesis of osteosarcoma.
Session 3B: The role of Disrupters of BMP9 (DONs) in regulating bone tumor formation from mesenchymal stem cells
Lecture Hall
It has become increasingly well-known that osteosarcoma is not only a genetic disease, but also a differentiation one that results from an osteoblast differentiation and proliferation imbalance. This study investigated how certain 19-base short regulatory RNAs may disrupt BMP9-induced osteoblast differentiation in mesenchymal stem cells (MSCs). We are interested in determining these effects because they may further explain the development of osteosarcoma.
Dr. He introduced a completely randomized 19-base short RNA Library into MSCs and discovered several short RNA transcripts, which are named as Disruptors of BMP9 (DONs). These DONs were shown to produce osteogenic resistant MSCs. Our candidate DONs are now being tested for their ability to disrupt osteogenic differentiation in MSCs. Within the coming months, we hope to uncover effective DONs and sequence its RNA to determine any up or down regulation of mRNA or lncRNA involved in the pathogenesis of osteosarcoma.